​

Niagen Bioscience Stock (NASDAQ:NAGE)

ForecastRevenueFinancialsChartTranscripts
Niagen Bioscience by TradingView

Previous Close

$7.57

52W Range

$3.49 - $14.69

50D Avg

$8.86

200D Avg

$8.75

Market Cap

$606.12M

Avg Vol (3M)

$1.10M

Beta

2.13

Div Yield

-

NAGE Company Profile

Niagen Bioscience Inc is a bioscience company dedicated to healthy aging. The Company leads research on nicotinamide adenine dinucleotide.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

104

IPO Date

Jun 24, 2015

Website

NAGE Performance

NAGE Financial Summary

Dec 24Dec 23Dec 22
Revenue$99.60M$83.57M$72.05M
Operating Income$7.73M$-5.60M$-18.63M
Net Income$8.55M$-4.94M$-16.54M
EBITDA$9.21M$-3.89M$-16.74M
Basic EPS$0.10$-0.07$-0.24
Diluted EPS$0.11$-0.07$-0.24

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q1 25May 10, 25 | 4:30 PM
Q4 24Mar 04, 25 | 4:30 PM
Q3 24Nov 01, 24 | 4:30 PM

Peer Comparison

TickerCompany
KALVKalVista Pharmaceuticals, Inc.
RGNXREGENXBIO Inc.
CMPXCompass Therapeutics, Inc.
KROSKeros Therapeutics, Inc.
GLUEMonte Rosa Therapeutics, Inc.
CTMXCytomX Therapeutics, Inc.
MNPRMonopar Therapeutics Inc.
SVRASavara Inc.
MLTXMoonLake Immunotherapeutics
ZVRAZevra Therapeutics, Inc.